Forte Biosciences Q2 net loss $(0.27)/share; FB102 phase 1 done, celiac study starts

Forte Biosciences, Inc.

2024-Q2 EPS reported -$0.43

Net loss per share $(0.27) for Q2 2024 vs $(0.42) for Q2 2023; six-month loss $(0.43) vs $(0.74).
Cash and equivalents $24.5M; operating expenses $12.8M (Q2 2024) vs $9.0M (Q2 2023).
FB102 phase 1 SAD/MAD healthy volunteer study completed with good safety and NK cell reduction.
Forte to initiate celiac disease patient study in Q3 2024; top-line data expected Q2 2025.
G&A expenses surged to $7.1M (Q2 2024) from $1.9M, driven by legal and professional costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.